vs
Protalix BioTherapeutics, Inc.（PLX）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$14.0M vs $9.1M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -60.3%，领先70.1%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-736.0K），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
PLX vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.5倍
$9.1M
营收增速更快
RVSB
高出60.3%
-49.9%
净利率更高
RVSB
高出70.1%
-60.3%
自由现金流更多
PLX
多$2.4M
$-736.0K
两年增速更快
RVSB
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $14.0M |
| 净利润 | $-5.5M | $1.4M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 12.4% |
| 净利率 | -60.3% | 9.8% |
| 营收同比 | -49.9% | 10.4% |
| 净利润同比 | -184.8% | 11.8% |
| 每股收益（稀释后） | $-0.06 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXRVSB
| Q4 25 | $9.1M | $14.0M | ||
| Q3 25 | $17.9M | $13.6M | ||
| Q2 25 | $15.7M | $13.3M | ||
| Q1 25 | $10.1M | $12.9M | ||
| Q4 24 | $18.2M | $12.7M | ||
| Q3 24 | $18.0M | $12.8M | ||
| Q2 24 | $13.5M | $12.2M | ||
| Q1 24 | — | $9.0M |
净利润PLXRVSB
| Q4 25 | $-5.5M | $1.4M | ||
| Q3 25 | $2.4M | $1.1M | ||
| Q2 25 | $164.0K | $1.2M | ||
| Q1 25 | $-3.6M | $1.1M | ||
| Q4 24 | $6.5M | $1.2M | ||
| Q3 24 | $3.2M | $1.6M | ||
| Q2 24 | $-2.2M | $966.0K | ||
| Q1 24 | — | $-3.0M |
毛利率PLXRVSB
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXRVSB
| Q4 25 | -51.1% | 12.4% | ||
| Q3 25 | 11.9% | 10.2% | ||
| Q2 25 | 7.5% | 11.7% | ||
| Q1 25 | -41.0% | 11.3% | ||
| Q4 24 | 39.6% | 12.4% | ||
| Q3 24 | 22.2% | 15.5% | ||
| Q2 24 | -18.0% | 10.0% | ||
| Q1 24 | — | -47.5% |
净利率PLXRVSB
| Q4 25 | -60.3% | 9.8% | ||
| Q3 25 | 13.2% | 8.1% | ||
| Q2 25 | 1.0% | 9.2% | ||
| Q1 25 | -35.8% | 8.9% | ||
| Q4 24 | 35.6% | 9.7% | ||
| Q3 24 | 18.0% | 12.2% | ||
| Q2 24 | -16.4% | 7.9% | ||
| Q1 24 | — | -34.7% |
每股收益（稀释后）PLXRVSB
| Q4 25 | $-0.06 | $0.07 | ||
| Q3 25 | $0.03 | $0.05 | ||
| Q2 25 | $0.00 | $0.06 | ||
| Q1 25 | $-0.05 | $0.05 | ||
| Q4 24 | $0.10 | $0.06 | ||
| Q3 24 | $0.03 | $0.07 | ||
| Q2 24 | $-0.03 | $0.05 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $164.2M |
| 总资产 | $82.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXRVSB
| Q4 25 | $14.7M | $28.6M | ||
| Q3 25 | $13.6M | $32.8M | ||
| Q2 25 | $17.9M | $34.2M | ||
| Q1 25 | $19.5M | $29.4M | ||
| Q4 24 | $19.8M | $25.3M | ||
| Q3 24 | $27.4M | $31.0M | ||
| Q2 24 | $23.4M | $27.8M | ||
| Q1 24 | — | $23.6M |
股东权益PLXRVSB
| Q4 25 | $48.2M | $164.2M | ||
| Q3 25 | $52.9M | $163.5M | ||
| Q2 25 | $49.9M | $162.0M | ||
| Q1 25 | $45.2M | $160.0M | ||
| Q4 24 | $43.2M | $158.3M | ||
| Q3 24 | $32.4M | $160.8M | ||
| Q2 24 | $28.6M | $155.9M | ||
| Q1 24 | — | $155.6M |
总资产PLXRVSB
| Q4 25 | $82.3M | $1.5B | ||
| Q3 25 | $82.3M | $1.5B | ||
| Q2 25 | $78.5M | $1.5B | ||
| Q1 25 | $73.9M | $1.5B | ||
| Q4 24 | $73.4M | $1.5B | ||
| Q3 24 | $61.6M | $1.5B | ||
| Q2 24 | $91.5M | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-736.0K |
| 自由现金流率自由现金流/营收 | 17.8% | -5.2% |
| 资本支出强度资本支出/营收 | 4.4% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $20.4M |
8季度趋势，按日历期对齐
经营现金流PLXRVSB
| Q4 25 | $2.0M | $-506.0K | ||
| Q3 25 | $-3.7M | $16.8M | ||
| Q2 25 | $-5.2M | $-697.0K | ||
| Q1 25 | $-5.1M | $8.3M | ||
| Q4 24 | $4.0M | $2.2M | ||
| Q3 24 | $4.1M | $764.0K | ||
| Q2 24 | $-3.6M | $5.4M | ||
| Q1 24 | — | $12.8M |
自由现金流PLXRVSB
| Q4 25 | $1.6M | $-736.0K | ||
| Q3 25 | $-4.2M | $16.4M | ||
| Q2 25 | $-5.7M | $-773.0K | ||
| Q1 25 | $-5.4M | $5.6M | ||
| Q4 24 | $3.6M | $1.9M | ||
| Q3 24 | $4.0M | $-1.4M | ||
| Q2 24 | $-3.8M | $5.3M | ||
| Q1 24 | — | $7.1M |
自由现金流率PLXRVSB
| Q4 25 | 17.8% | -5.2% | ||
| Q3 25 | -23.7% | 120.1% | ||
| Q2 25 | -36.2% | -5.8% | ||
| Q1 25 | -53.0% | 43.1% | ||
| Q4 24 | 19.6% | 15.0% | ||
| Q3 24 | 22.4% | -11.3% | ||
| Q2 24 | -28.1% | 43.7% | ||
| Q1 24 | — | 79.0% |
资本支出强度PLXRVSB
| Q4 25 | 4.4% | 1.6% | ||
| Q3 25 | 2.8% | 2.9% | ||
| Q2 25 | 2.8% | 0.6% | ||
| Q1 25 | 3.0% | 21.0% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.5% | 17.3% | ||
| Q2 24 | 1.3% | 0.9% | ||
| Q1 24 | — | 62.0% |
现金转化率PLXRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | -1.58× | 15.25× | ||
| Q2 25 | -31.91× | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | 0.61× | 1.79× | ||
| Q3 24 | 1.27× | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RVSB
暂无分部数据
